News

March 23, 2018March 23, 2018

Tecentriq Combination Shows Positive Interim Results for Untreated Advanced Lung Cancer in Phase 3 Trial

News

Tecentriq (atezolizumab) in combination with chemotherapy reduces the risk of disease progression or death in people with previously untreated advanced squamous non-small cell lung cancer (NSCLC), according to interim data from Roche‘s ... Read more

March 22, 2018March 22, 2018

Cesca Therapeutics Files Patent to Simplify Development of CAR T-cell Immunotherapies

News

Cesca Therapeutics filed a new patent application that may simplify the development of cancer immunotherapies, potentially improving efficiency and reducing manufacturing costs, the company announced. The application was submitted to ... Read more

March 21, 2018March 21, 2018

Investigational T-Cell Therapy Promising in First Liposarcoma Patients in Phase 1/2 Trial

News

NY-ESO SPEAR T-cells, an investigational therapy by Adaptimmune Therapeutics, showed promise as a treatment for myxoid/round cell liposarcoma (MRCLS) in the first four patients in an ongoing Phase 1/2 clinical trial. ... Read more

March 20, 2018March 20, 2018

UCLA Uses Magnetic Fields to Deliver Gene Therapy-carrying Nanospears to Cells

News

UCLA researchers have developed what they call nanospears to deliver molecules such as genes into selected cells with pinpoint accuracy. The new method, which uses magnetic fields to deliver the needlelike nanostructres, overcomes ... Read more

March 19, 2018March 19, 2018

Clinical Trial of Vaccine, IO102, Plus Keytruda in Advanced NSCLC Patients Planned

News

IO Biotech and Merck & Co recently signed an agreement to assess IO Biotech’s lead candidate IO102, an anti-cancer vaccine, in combination with Keytruda (pembrolizumab) in patients with metastatic non-small cell ... Read more

March 16, 2018March 16, 2018

FDA Grants Priority Review to Keytruda for Advanced Cervical Cancer

News

The U.S. Food and Drug Administration will be giving priority review to Merck’s Keytruda (pembrolizumab) as a treatment for women whose advanced cervical cancer progressed during or after chemotherapy. Priority review ... Read more

March 15, 2018March 15, 2018

Polyphor Planning Pivotal Trial of Its Breast Cancer Therapy Balixafortide

News

Polyphor is planning a pivotal clinical trial of its metastatic breast cancer therapy balixafortide (POL6326) after an encouraging meeting with U.S. regulators. The meeting dealt with the preliminary results of a Phase ... Read more

March 14, 2018March 14, 2018

New Type of CAR T-cells Offers Hope for ‘First Viable’ Treatment of T-cell Blood Cancers, Study Reports

News

A new approach using genetically modified T-cells may become the first clinically viable, targeted immunotherapy for T-cell blood cancers, a preclinical study reports. The study, “An “off-the-shelf” fratricide-resistant CAR-T for ... Read more

March 13, 2018March 13, 2018

As More Cancer Patients Enroll in Early Stage Clinical Trials, Researchers Ask ‘Why?’

News

The determination to fight cancer and having access to the best cancer treatments seem to be the top reasons why more patients participate in early stage clinical trials, new research ... Read more

March 12, 2018March 12, 2018

Phase 3 Trial of Idera’s IMO-2125 Combo Therapy Is Recruiting Advanced Melanoma Patients

News

A new Phase 3 trial for advanced melanoma patients who failed to respond to Opdivo (nivolumab) or Keytruda (pembrolizumab) is recruiting participants to evaluate Idera Pharmaceutical‘s experimental immunotherapy, IMO-2125, in combination with ... Read more